Results from phase IV study of Mydcombi (phenylephrine + tropicamide) to characterize the lowest deliverable dose for mydriasis – Eyenovia
Eyenovia announced results from a Phase IV study of Mydcombi designed to characterize the lowest deliverable dose for mydriasis (pupil dilation). Mydcombi is the only FDA-approved fixed dose… read more.
